ATHERSYS, INC / NEW Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2015-12-18: Form 8-K; Period of report 2015-12-17; Description 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; Details 1.01.
- 2015-11-05: Form 8-K; Period of report 2015-11-05; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2015-10-21: Form 8-K; Period of report 2015-10-20; Description 1.02 Termination of a Material Definitive Agreement; 8.01 Other Events; Details 1.02.
- 2015-08-06: Form 8-K; Period of report 2015-08-06; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2015-12-18 | 8-K | 2015-12-17 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. 3.02 The information contained above in Item 1.01 is hereby incorporated by reference into this Item 3.02. | d107763d8k.htm |
| 2015-11-05 | 8-K | 2015-11-05 | 2.02 Results of Operations and Financial Condition | 2.02 On November 5, 2015, Athersys, Inc. issued a press release announcing financial results for its third quarter ended September 30, 2015. | d17771d8k.htm |
| 2015-10-21 | 8-K | 2015-10-20 | 1.02 Termination of a Material Definitive Agreement; 8.01 Other Events | 1.02 On October 20, 2015, Athersys, Inc., ABT Holding Company, a subsidiary of Athersys, Inc. (together, “Athersys” or the “Company”), and Chugai Pharmaceutical Co. Ltd. (“Chugai”) agreed to terminate the License Agreement (the “Agreement”) dated February 28, 2015 between the parties, reflecting an inability to reach an agreement on the modification of the financial terms of the Agreement and on the development strategy of the Company’s MultiStem® cell therapy for the treatment of ischemic stroke in Japan. 8.01 On October 21, 2015, the Company announced the termination of the collaboration with Chugai to develop and commercialize MultiStem cell therapy for the treatment of ischemic stroke in Japan, and the entering into a letter of intent with a Japanese company for the development and commercialization of MultiStem therapy for several indications in Japan, including ischemic stroke. | d25186d8k.htm |
| 2015-08-06 | 8-K | 2015-08-06 | 2.02 Results of Operations and Financial Condition | 2.02 On August 6, 2015, Athersys, Inc. issued a press release announcing financial results for its second quarter ended June 30, 2015. | d70491d8k.htm |
| 2015-06-25 | 8-K | 2015-06-24 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 Athersys, Inc. (the “Company”) held its Annual Meeting of Stockholders on June 24, 2015. | d949655d8k.htm |
| 2015-05-11 | 8-K | 2015-05-11 | 2.02 Results of Operations and Financial Condition | 2.02 On May 11, 2015, Athersys, Inc. issued a press release announcing financial results for its first quarter ended March 31, 2015. | d923935d8k.htm |
| 2015-04-17 | 8-K | 2015-04-17 | 8.01 Other Events | 8.01 On April 17, 2015, Athersys, Inc. (“Athersys”) announced the preliminary results of its Phase 2 clinical trial using MultiStem® cell therapy to treat patients who have suffered an ischemic stroke. | d912191d8k.htm |
| 2015-03-12 | 8-K | 2015-03-12 | 2.02 Results of Operations and Financial Condition | 2.02 On March 12, 2015, Athersys, Inc. issued a press release announcing financial results for its fourth quarter ended December 31, 2014. | d887602d8k.htm |
| 2015-03-05 | 8-K | 2015-02-28 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d886442d8k.htm |
| 2015-03-02 | 8-K | 2015-03-01 | 8.01 Other Events | 8.01 On March 1, 2015, Athersys, Inc. (“Athersys”) announced a collaboration with Chugai Pharmaceutical Co., Ltd. (“Chugai”) to develop and commercialize MultiStem® cell therapy for ischemic stroke in Japan. | d883529d8k.htm |
| 2015-01-29 | 8-K | 2015-01-27 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | d859707d8k.htm |